GO:0045742 positive regulation of epidermal growth factor receptor signaling pathway: Signaling Amplification, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0045742 describes any process that activates or increases the frequency, rate or extent of epidermal growth factor receptor (EGFR) signaling pathway activity.
• Positive regulation of EGFR signaling is achieved through ligand availability, receptor stabilization, feedback inhibition relief, and crosstalk with other receptors such as MET and integrins [1,4,8].
• Dysregulated positive regulation of EGFR signaling drives resistance to EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer (NSCLC) via mechanisms including IFITM3-MET interaction and cancer-associated fibroblast feedback loops [1,2].
• The term is relevant beyond cancer: GOLM1 activates macrophage EGFR-ERK signaling to promote atherogenesis, and CEBPD augments hypoxia-induced invasion through EGFR/PI3K pathway in glioblastoma [4,6].
• Key positive regulators include EGFR itself, MET, STAT3, UTX, NONO, CTHRC1, and GOLM1, which can be studied using CRISPR knockout, knock-in, and overexpression models [1,2,5,6,7].
• Experimental approaches such as phospho-EGFR profiling, RNA-seq, and CRISPR library screening are essential to dissect positive regulation of EGFR signaling in disease contexts [1,2,3].
Description
The epidermal growth factor receptor (EGFR) signaling pathway is a central regulator of cell proliferation, survival, migration, and differentiation. GO:0045742, positive regulation of epidermal growth factor receptor signaling pathway, encompasses any process that activates or increases the frequency, rate or extent of EGFR signaling activity. This term is critical for understanding how cells amplify EGFR signals under physiological conditions and how cancer cells hijack these mechanisms to drive tumor progression and therapy resistance [1,2]. Positive regulation can occur at multiple levels, including increased ligand availability, receptor stabilization, enhanced downstream signaling, and relief from negative feedback inhibition. In non-small cell lung cancer (NSCLC), positive regulation of EGFR signaling is frequently dysregulated, leading to resistance to EGFR tyrosine kinase inhibitors (TKIs) such as osimertinib [1,2]. For example, IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant NSCLC, while cancer-associated fibroblasts promote EGFR-TKI resistance via a CTHRC1/glycolysis/H3K18la positive feedback loop. Beyond cancer, positive regulation of EGFR signaling contributes to atherosclerosis through GOLM1-mediated activation of macrophage EGFR-ERK signaling and to glioblastoma invasion via CEBPD-driven EGFR/PI3K pathway activation. Understanding the molecular players and regulatory mechanisms of GO:0045742 is therefore essential for developing targeted therapies and for designing CRISPR-based experiments to dissect causal relationships [3,5,7].
positive regulation of epidermal growth factor receptor signaling pathway At A Glance
| GO ID | GO:0045742 |
|---|---|
| GO term | positive regulation of epidermal growth factor receptor signaling pathway |
| Ontology | biological_process |
| Synonym | activation of epidermal growth factor receptor signaling pathway; positive regulation of EGF receptor signaling pathway; positive regulation of EGFR signaling pathway; stimulation of epidermal growth factor receptor signaling pathway; upregulation of epidermal growth factor receptor signaling pathway |
| Major function | Increases the frequency, rate or extent of EGFR signaling pathway activity |
| Related pathways | EGFR-ERK, EGFR-AKT, EGFR-PI3K, MET crosstalk [1,4,6] |
| Disease relevance | Cancer (NSCLC, glioblastoma, triple-negative breast cancer), atherosclerosis [1,2,4,6,7] |
| Key regulators | EGFR, MET, STAT3, UTX, NONO, CTHRC1, GOLM1, IFITM3 [1,2,5,6,7] |
What Is GO:0045742?
GO:0045742 is defined as any process that activates or increases the frequency, rate or extent of epidermal growth factor receptor signaling pathway activity. In other words, it includes molecular events that positively regulate the EGFR signaling cascade, such as enhancing receptor activation, promoting downstream phosphorylation events, or counteracting negative feedback inhibitors.
Why Is positive regulation of epidermal growth factor receptor signaling pathway Important in Cell Biology?
Positive regulation of EGFR signaling is a fundamental process that amplifies cellular responses to growth factors. Its dysregulation is a hallmark of many cancers, where increased EGFR signaling promotes proliferation, survival, and therapy resistance [1,2]. Understanding GO:0045742 helps researchers identify novel therapeutic targets and biomarkers, and it guides the design of CRISPR-based models to study gene function in disease contexts [3,5,7].
• Drives resistance to EGFR-targeted therapies in NSCLC, including osimertinib and other TKIs [1,2].
• Promotes tumor progression in glioblastoma through hypoxia-induced EGFR/PI3K signaling.
• Contributes to triple-negative breast cancer tumorigenesis via nuclear EGFR and NONO.
• Enhances immunosuppression and reduces efficacy of anti-PD-L1 therapy in EGFR-activated NSCLC.
• Plays a role in atherosclerosis by activating macrophage EGFR-ERK signaling.
• Involves transcriptional upregulation of UTX via STAT3 in NSCLC.
• Serves as a target for CRISPR knockout and knock-in studies to dissect causal mechanisms [1,2,5].
• Can be modulated by feedback inhibitors, offering opportunities for therapeutic intervention.
• Relevant to understanding crosstalk between EGFR and other receptor tyrosine kinases like MET.
• Provides a framework for identifying biomarkers of drug resistance and disease progression [2,3].
What Happens During positive regulation of epidermal growth factor receptor signaling pathway?
Ligand Availability and Receptor Activation
In simple terms: More growth factors or better receptor activation means stronger EGFR signals.
Positive regulation can begin with increased availability of EGFR ligands such as EGF, TGF-alpha, or amphiregulin, or with enhanced receptor dimerization and autophosphorylation. Inducible feedback inhibitors normally dampen EGFR signaling, and their relief or downregulation can amplify the pathway. In cancer, cancer-associated fibroblasts can secrete factors like CTHRC1 that promote EGFR-TKI resistance through a glycolysis/H3K18la positive feedback loop, effectively increasing EGFR signaling.
Receptor Stabilization and Crosstalk
In simple terms: Other proteins can stabilize EGFR or help it signal from inside the cell.
Positive regulation often involves protein-protein interactions that stabilize EGFR or facilitate its nuclear translocation. For example, IFITM3 interacts with MET to drive osimertinib resistance through AKT pathway activation in EGFR-mutant NSCLC. The RNA-binding protein NONO potentiates nuclear EGFR-mediated tumorigenesis in triple-negative breast cancer. Integrin-mediated crosstalk can also augment EGFR/PI3K signaling in glioblastoma.
Downstream Signaling Amplification
In simple terms: Once EGFR is active, downstream pathways like PI3K/AKT and ERK are turned up.
Positive regulation extends to downstream effectors. EGFR transcriptionally upregulates UTX via STAT3 in NSCLC, which can further enhance oncogenic signaling. In macrophages, GOLM1 promotes atherogenesis by activating the EGFR-ERK signaling cascade. These examples illustrate how positive regulation can occur at multiple nodes, from receptor to transcription factor.
Feedback Inhibition and Its Relief
In simple terms: Cells normally put brakes on EGFR signaling; positive regulation can remove those brakes.
Inducible feedback inhibitors are key negative regulators of EGFR signaling. Positive regulation of GO:0045742 can occur when these inhibitors are downregulated or bypassed. For instance, hypoxia-induced CEBPD augments invasion through extracellular matrix-integrin mediated EGFR/PI3K pathway, potentially overriding feedback inhibition. Understanding these mechanisms is crucial for designing therapies that target positive regulators.
Key Genes Involved in GO:0045742 positive regulation of epidermal growth factor receptor signaling pathway
The following genes and proteins are experimentally validated positive regulators or effectors of EGFR signaling, based on the provided literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EGFR | Receptor tyrosine kinase; initiates signaling upon ligand binding | Central to GO:0045742; target of TKIs; mutated in NSCLC [1,2,5] |
| MET | Receptor tyrosine kinase; crosstalk with EGFR | IFITM3-MET interaction drives osimertinib resistance |
| IFITM3 | Interferon-induced transmembrane protein; interacts with MET | Promotes AKT pathway activation and TKI resistance |
| CTHRC1 | Secreted protein from cancer-associated fibroblasts | Promotes EGFR-TKI resistance via glycolysis/H3K18la loop |
| STAT3 | Transcription factor downstream of EGFR | Mediates EGFR-induced UTX upregulation |
| UTX | Histone demethylase; transcriptionally upregulated by EGFR/STAT3 | Epigenetic regulator in NSCLC |
| NONO | RNA-binding protein; potentiates nuclear EGFR | Drives triple-negative breast cancer tumorigenesis |
| GOLM1 | Golgi membrane protein; activates EGFR-ERK | Promotes atherogenesis in macrophages |
| CEBPD | Transcription factor induced by hypoxia | Augments invasion via EGFR/PI3K in glioblastoma |
| ILT4 | Immunoglobulin-like transcript 4; immunosuppressive | Inhibition enhances anti-PD-L1 therapy in EGFR-activated NSCLC |
| AKT | Serine/threonine kinase downstream of EGFR | Mediates survival signaling; activated by IFITM3-MET |
| ERK | Mitogen-activated protein kinase downstream of EGFR | Mediates proliferative signals; activated by GOLM1 |
| PI3K | Phosphatidylinositol 3-kinase; downstream of EGFR | Mediates invasion in glioblastoma |
| H3K18la | Histone lactylation mark | Part of CTHRC1/glycolysis feedback loop |
| Integrins | Cell adhesion receptors; crosstalk with EGFR | Mediate ECM-integrin-EGFR/PI3K signaling |
| PD-L1 | Immune checkpoint ligand | Anti-PD-L1 efficacy enhanced by ILT4 inhibition |
| TAMs | Tumor-associated macrophages | Mediate immunosuppression in EGFR-activated NSCLC |
| T cells | Immune effector cells | Dysfunctional T cells in EGFR-activated tumors |
How Is positive regulation of epidermal growth factor receptor signaling pathway Regulated?
Positive regulation of EGFR signaling is itself tightly controlled by feedback mechanisms. Inducible feedback inhibitors can be upregulated in response to EGFR activation to dampen the signal. In cancer, this regulation is often disrupted. For example, cancer-associated fibroblasts can create a positive feedback loop involving CTHRC1, glycolysis, and H3K18la that sustains EGFR signaling and TKI resistance. Similarly, IFITM3-MET interaction can bypass normal regulatory checkpoints to activate AKT. Understanding these regulatory circuits is essential for identifying therapeutic vulnerabilities.
positive regulation of epidermal growth factor receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IFITM3 | Osimertinib resistance in EGFR-mutant NSCLC | Knockout in NSCLC cell lines; overexpression; phospho-AKT profiling |
| CTHRC1 | EGFR-TKI resistance via CAF-mediated feedback | Knockout in cancer-associated fibroblasts; co-culture with NSCLC cells |
| CEBPD | Hypoxia-induced invasion in glioblastoma | Knockout under hypoxia; invasion assays; EGFR/PI3K readouts |
| NONO | Triple-negative breast cancer tumorigenesis | Knockout; nuclear EGFR imaging; xenograft models |
| GOLM1 | Atherogenesis via macrophage EGFR-ERK | Knockout in macrophages; atherosclerosis mouse models |
EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)
Positive regulation of EGFR signaling is a major driver of resistance to EGFR TKIs like osimertinib. IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation. Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1/glycolysis/H3K18la positive feedback loop. Additionally, ILT4 inhibition can prevent immunosuppression and enhance anti-PD-L1 therapy in NSCLC with EGFR activation. EGFR also transcriptionally upregulates UTX via STAT3, contributing to oncogenesis.
Glioblastoma
In glioblastoma, hypoxia induces CEBPD, which augments invasion through extracellular matrix-integrin mediated EGFR/PI3K pathway activation. This highlights how positive regulation of EGFR signaling can be driven by the tumor microenvironment.
Triple-Negative Breast Cancer (TNBC)
The RNA-binding protein NONO potentiates nuclear EGFR-mediated tumorigenesis in TNBC, representing a mechanism of positive regulation that occurs in the nucleus.
Atherosclerosis
GOLM1 promotes atherogenesis by activating macrophage EGFR-ERK signaling cascade, demonstrating a role for positive regulation of EGFR signaling in cardiovascular disease.
From positive regulation of epidermal growth factor receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of IFITM3 reverse osimertinib resistance? | CRISPR knockout of IFITM3 in EGFR-mutant NSCLC cells |
| Can CTHRC1 knockout in CAFs overcome TKI resistance? | CRISPR knockout in cancer-associated fibroblasts; co-culture |
| Does NONO knockout reduce nuclear EGFR signaling? | CRISPR knockout in TNBC cells; subcellular fractionation |
| Does GOLM1 overexpression enhance macrophage EGFR-ERK? | CRISPR overexpression in macrophages; phospho-ERK assays |
| Does CEBPD knockout impair hypoxia-induced invasion? | CRISPR knockout in glioblastoma cells under hypoxia |
| Does UTX knock-in mimic EGFR/STAT3 upregulation? | CRISPR knock-in of UTX in NSCLC cells |
How to Study the positive regulation of epidermal growth factor receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Phospho-EGFR ELISA | Activation status of EGFR | Quantify positive regulation after ligand stimulation |
| Western blot for phospho-AKT/ERK | Downstream pathway activation | Assess IFITM3-MET or GOLM1 effects [1,6] |
| RNA-seq | Transcriptional changes | Identify UTX or CEBPD target genes [4,5] |
| CRISPR knockout screening | Gene essentiality and resistance | Discover novel positive regulators in NSCLC [1,2] |
| Immunofluorescence | Subcellular localization | Study nuclear EGFR with NONO |
| Co-culture assays | Cell-cell interactions | Model CAF-mediated TKI resistance |
| Invasion assays | Cell migration and invasion | Assess CEBPD-driven glioblastoma invasion |
| Macrophage polarization assays | Immune cell phenotype | Study GOLM1 in atherosclerosis |
Phospho-Proteomics and Western Blotting
Measuring phosphorylation of EGFR, AKT, and ERK is essential to quantify positive regulation. For example, IFITM3-MET interaction drives AKT pathway activation, which can be detected by phospho-AKT antibodies. GOLM1-mediated EGFR-ERK activation can be assessed by phospho-ERK Western blotting.
RNA Sequencing and Transcriptomics
RNA-seq can identify transcriptional changes driven by positive regulators. EGFR transcriptionally upregulates UTX via STAT3, which can be validated by RNA-seq after EGFR activation or STAT3 inhibition. CEBPD target genes under hypoxia can also be profiled.
CRISPR Library Screening
Genome-wide CRISPR screens can identify novel positive regulators of EGFR signaling. For instance, screens in EGFR-mutant NSCLC cells under TKI treatment can uncover genes whose knockout sensitizes cells to osimertinib [1,2].
Imaging and Subcellular Fractionation
Nuclear EGFR signaling can be studied by immunofluorescence and subcellular fractionation. NONO potentiates nuclear EGFR-mediated tumorigenesis, which can be visualized by co-localization studies.
How CRISPR Can Be Used to Study GO:0045742 positive regulation of epidermal growth factor receptor signaling pathway
Knockout
CRISPR knockout is used to eliminate positive regulators and assess their impact on EGFR signaling. For example, knocking out IFITM3 in EGFR-mutant NSCLC cells can reverse osimertinib resistance and reduce AKT activation. Knocking out CTHRC1 in cancer-associated fibroblasts can disrupt the glycolysis/H3K18la feedback loop and restore TKI sensitivity. NONO knockout in TNBC cells can reduce nuclear EGFR-mediated tumorigenesis.
Point Mutation
Point mutations can mimic activating or inactivating events in positive regulators. For instance, mutating phosphorylation sites on STAT3 or UTX can test their role in EGFR-driven transcription. Point mutations in EGFR itself (e.g., L858R) are common in NSCLC and can be modeled to study positive regulation.
Knock-in
Knock-in of tagged or mutant versions of genes allows precise tracking and functional studies. For example, knocking in a tagged UTX can help study its interaction with STAT3 downstream of EGFR. Knock-in of fluorescently tagged NONO can reveal its nuclear localization dynamics.
Overexpression
Overexpression of positive regulators can amplify EGFR signaling. Overexpressing GOLM1 in macrophages enhances EGFR-ERK activation and promotes atherogenesis. Overexpressing CEBPD under hypoxia augments invasion through EGFR/PI3K in glioblastoma. These models are useful for gain-of-function studies.
How EDITGENE Supports positive regulation of epidermal growth factor receptor signaling pathway Research
Researchers studying positive regulation of epidermal growth factor receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in amplifying EGFR signals, driving disease, or mediating therapy resistance. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of epidermal growth factor receptor signaling pathway research.
Frequently Asked Questions About positive regulation of epidermal growth factor receptor signaling pathway
What is GO:0045742?
GO:0045742 is the Gene Ontology term for positive regulation of epidermal growth factor receptor signaling pathway, defined as any process that activates or increases the frequency, rate or extent of EGFR signaling activity.
What genes are involved in positive regulation of EGFR signaling?
Key genes include EGFR, MET, IFITM3, CTHRC1, STAT3, UTX, NONO, GOLM1, and CEBPD, among others [1,2,4,5,6,7].
How does positive regulation of EGFR signaling contribute to cancer?
It drives tumor proliferation, survival, and resistance to EGFR TKIs like osimertinib, often through crosstalk with MET or feedback loops involving cancer-associated fibroblasts [1,2].
What is the role of IFITM3 in EGFR signaling?
IFITM3 interacts with MET to drive osimertinib resistance through AKT pathway activation in EGFR-mutant NSCLC.
How can CRISPR be used to study GO:0045742?
CRISPR knockout, knock-in, point mutation, and overexpression models allow researchers to test the causal role of specific genes in positive regulation of EGFR signaling [1,2,5,7].
What diseases are associated with positive regulation of EGFR signaling?
Diseases include non-small cell lung cancer, glioblastoma, triple-negative breast cancer, and atherosclerosis [1,2,4,6,7].
What is the role of CTHRC1 in EGFR-TKI resistance?
CTHRC1 from cancer-associated fibroblasts promotes EGFR-TKI resistance via a glycolysis/H3K18la positive feedback loop.
How does NONO regulate EGFR signaling?
NONO potentiates nuclear EGFR-mediated tumorigenesis in triple-negative breast cancer.
What experimental models are used to study positive regulation of EGFR signaling?
Common models include CRISPR knockout cell lines, overexpression models, co-culture systems, and xenografts [1,2,4,6].
What services does EDITGENE offer for EGFR signaling research?
EDITGENE provides CRISPR knockout, point mutation, knock-in, overexpression cell models, CRISPR library screening, and bioinformatics services [1,2,3,4,5,6,7].
Conclusion
GO:0045742, positive regulation of epidermal growth factor receptor signaling pathway, is a critical biological process that amplifies EGFR signals and contributes to cancer progression, therapy resistance, and other diseases. Understanding its molecular players and regulatory mechanisms is essential for developing targeted therapies. EDITGENE offers a comprehensive suite of CRISPR services to help researchers dissect these mechanisms and accelerate discovery.
References
- 1. Ibusuki R et al.. 2025. IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancer.. Mol Cancer 24(1):272 PMID: 41152910
- 2. Zhang C et al.. 2025. Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1/glycolysis/H3K18la positive feedback loop.. Oncogene 44(19):1400-1414 PMID: 40011576
- 3. Chen X et al.. 2021. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.. Theranostics 11(7):3392-3416 PMID: 33537094
- 4. Mao XG et al.. 2023. CEBPD is a master transcriptional factor for hypoxia regulated proteins in glioblastoma and augments hypoxia induced invasion through extracellular matrix-integrin mediated EGFR/PI3K pathway.. Cell Death Dis 14(4):269 PMID: 37059730
- 5. Zhou L et al.. 2022. EGFR transcriptionally upregulates UTX via STAT3 in non-small cell lung cancer.. J Cancer Res Clin Oncol 148(2):309-319 PMID: 34661759
- 6. Gai X et al.. 2025. GOLM1 Promotes Atherogenesis by Activating Macrophage EGFR-ERK Signaling Cascade.. Circ Res 136(8):848-861 PMID: 40026146
- 7. Shen M et al.. 2022. RNA-binding protein p54(nrb)/NONO potentiates nuclear EGFR-mediated tumorigenesis of triple-negative breast cancer.. Cell Death Dis 13(1):42 PMID: 35013116
- 8. Segatto O et al.. 2011. Regulation of epidermal growth factor receptor signalling by inducible feedback inhibitors.. J Cell Sci 124(Pt 11):1785-93 PMID: 21576352
